What are nanoantibodies?

Nanoantibodies (nAbs) are single-domain peptides of ~110 amino acids, comprising an antigen- binding domain of a camelid heavy-chain only antibody.

  • nAbs have many advantages over conventional antibodies: high affinity (frequently nM range), high permeability to tissues (can cross blood brain barrier), access to buried epitopes, high stability, and low production cost.
  • nAbs are amenable to the state-of- the-art antibody engineering including humanization and drug conjugation.
camelid derived antibody
conventional antibody

Linking multiple nAbs into a breakthrough biologic drug

Linking multiple nAbs into a single linear antibody molecule with multiple valencies and/or specificities is a simple process and can drastically increase drug efficacy by:

  • Increasing the affinity and stability of the biologic drug
  • Endowing the molecule with a unique target specificity
multivalent nAb drug
bi-paratopic nAb drug
multi-specfic nAb drug

Active Programs

Allele Biotechnology has received multiple federal grants over the past decade to identify new nAbs against dozens of clinically important targets. Based on these nAbs, we have multiple drug candidates currently in the advanced stage of pre-clinical development. Our focus areas and targets include:

  • Immunology – Cytokines, cytokine receptors, immune checkpoint molecules, and lymphocyte markers. Our most advanced drug candidate in this area is ALL-I- 0143, which is a bi-specific nAb drug being developed as a sepsis therapeutic. Additional targets currently in development include CD3, CD4, CD14, CD16, IL2, PD1L and GITR.
  • Oncology – Oncogenic molecules and markers from various types of human cancers. ALL-C- 2137 and ALL-C- 2224, which target HER2 and EGFR respectively, are in the advanced stage of pre-clinical study. Other targets currently in development include VEGF, FGF2, CD19 and CD20 and OX40.
  • Neurology – Pathogenic molecules that are involved in the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and ALS. These include oligomeric amyloid beta, as well as neural protective proteins such as FG01.

In addition to drug development a number of nanoantibodies are evaluation and formulation for FDA approved (510k) clinical diagnostics, target examples include p16, Ki67, and p53. Allele Biotechnology also had an active catalog of nanoantibodies available for research, to view nAb’s currently available for research purposes against common targets like fluorescent proteins click here

Nanoantibody Development at Allele Biotechnology

For more information about our programs or to inquire about licensing or partnering please complete the form below.


Please copy the characters from the image into the text field below. Doing this helps us prevent automated submissions.